Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v25-EN Version v13-FR
Language English French
Date Updated 2019-02-20 2018-04-12
Drug Identification Number 00578657 00578657
Brand name EPIPEN JR EPIPEN JR
Common or Proper name EPIPEN JR EPIPEN JR
Company Name MYLAN SPECIALTY LP MYLAN SPECIALTY LP
Ingredients EPINEPHRINE EPINEPHRINE
Strength(s) 0.5MG 0.5MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size Each (0.15MG/0.3ML AUTO-INJECTOR) Each (0.15MG/0.3ML AUTO-INJECTOR)
ATC code C01CA C01CA
ATC description CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2018-04-16 2018-04-16
Actual start date 2018-04-16
Estimated end date Unknown
Actual end date 2019-02-19
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Pfizer Canada is experiencing supply constraints of EpiPen auto-injectors in the 0.3 mg and 0.15 mg formats. Available EpiPen supply will be managed through measured national allocation to wholesalers.
Health Canada comments http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/67330a-eng.php